The Diabetic Retinopathy Clinical Research Network has published the 2-year results of a 5-year study comparing intravitreous ranibizumab with panretinal laser photocoagulation in patients with proliferative diabetic retinopathy. The results suggest that intravitreous ranibizumab will become a valuable treatment option, although its exact role remains to be defined.
- diabetes complications
- drug therapy
- eye diseases
Gibson, J. M., & McGinnigle, S. (2016). Diabetes : intravitreous ranibizumab for proliferative diabetic retinopathy. Nature Reviews Endocrinology, 12(3), 130-131. https://doi.org/10.1038/nrendo.2016.1